Neurodex Inc.
Natick, MA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 27 Strathmore Rd, Natick, MA 01760, USA
- Website
- neurodex.co
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Translational Genomics Research Institute | R24NS132738 | $770,708 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Amprion, Inc. | San Francisco, CA | 621511 Medical Laboratories |
| Captis Diagnostics Inc. | Pittsburgh, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Numentus Technologies Inc. | Menlo Park, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| CND Life Sciences, Inc. | Scottsdale, AZ | 621511 Medical Laboratories |
| Aivocode, Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Neurodex Inc. is a corporate entity registered in SAM.gov, specializing in advanced biomedical research and diagnostic technology development, with a focused expertise in neurodegenerative disease biomarkers. The company appears to be a small, for-profit organization that develops innovative diagnostic technologies, particularly in the field of neuroscience, with a specific emphasis on extracellular vesicle (EV) isolation and analysis techniques. Neurodex provides sophisticated scientific services to federal agencies, primarily focusing on developing blood-based biomarker technologies for neurological disorders such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions.
Regarding federal contract awards, Neurodex Inc. has demonstrated a targeted approach in scientific research, with a notable contract from the National Institute on Aging (NIA) involving a precise scientific investigation. The contract, valued at $24,750 and completed in February 2021, focused on isolating and quantitatively characterizing brain-derived exosomes from plasma samples in a clinical trial context related to Alzheimer's disease progression. The contract was a standard purchase order without any specific set-aside designations, indicating a competitive, merit-based award process based on the company's specialized scientific capabilities.
In terms of federal grant awards, Neurodex Inc. has secured multiple significant grants from prestigious agencies like the National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), and the Defense Health Agency. These grants, totaling several million dollars, support advanced research in developing blood-based biomarker technologies for neurological disorders. Key grant projects include developing diagnostic methods for ALS, frontotemporal dementia, and Alzheimer's disease, with a specific focus on innovative techniques like the EXOSORT technology for isolating neuron-derived extracellular vesicles. The grants demonstrate Neurodex's commitment to advancing neurological disease diagnostics, with projects aimed at improving patient stratification, treatment response tracking, and diagnostic capabilities through sophisticated biomarker detection and analysis methodologies.
SBA capabilities narrative
Exosome-based blood diagnostic
Quick answers
Is Neurodex Inc. registered in SAM.gov?
Yes. Neurodex Inc.'s SAM.gov registration is active through March 23, 2027.
What is Neurodex Inc.'s CAGE code?
Neurodex Inc.'s CAGE code is 85YN0, and its Unique Entity ID (UEI) is CK9RG13HMKN5.
What is Neurodex Inc.'s most recent federal award?
Neurodex Inc.'s most recent federal grant award is Blood-based biomarker for characterizing progression and therapeutic response in amyotrophic lateral sclerosis - in… (R44NS137901), from National Institute of Neurological Disorders and Stroke (NIH), on September 1, 2024.
On GovTribe
See Neurodex Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors